Alembic Pharma to launch 25 drugs in US generic segment in FY25 indiainfoline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiainfoline.com Daily Mail and Mail on Sunday newspapers.
Revenues grew 8% to Rs.1595 crore in Q2FY24 compared to Rs 1475 crore last year. The earnings before interest, tax, depreciation and amortization (EBITA) declined 6% YoY to Rs 218 crore. The EBITDA margins stood at 14% in Q2FY24.
Youngest TiE chapter Vadodara announces mega event on Oct 20-21 themed 'Opportunities Unlimited' bilkulonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bilkulonline.com Daily Mail and Mail on Sunday newspapers.
Alembic Pharmaceuticals plans to launch 20 new products in the US market in FY24, including oncology and non-oncology injectables, derma, and ophthalmic products. The launches will be facilitated by the newly USFDA-compliant facilities. The company also plans to take advantage of drug shortages in the US.
Alembic Pharma has reported a Q1 net profit of INR 121 crore, up from a net loss of INR 66 crore YoY, led by increased sales growth across its segments. The Indian branded business recorded a 9% YoY growth to INR 524 crore, while US generics saw 6% YoY growth to INR 354 crore.